Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

Development of FKBP51-Inhibitors to treat stress-related disorders: assessment of feasibility

Objective

The FK506-binding protein 51 (FKBP51) plays an important role in the human stress response. In research funded by my ERC Starting Grant I identified the molecular mechanisms of how a de-repressed FKBP51 mediates stress- and trauma-induced risk for psychiatric disorders in genetically vulnerable individuals, thus validating FKBP51 as a potential drug target for stress-related disorders. The current proof-of-concept proposal aims at providing a due diligence analysis to support the concept that the development of FKBP51-directed drugs is technically feasible and economically warranted.

Fields of science

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

Call for proposal

ERC-2013-PoC
See other projects for this call

Host institution

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
EU contribution
€ 150 000,00
Address
HOFGARTENSTRASSE 8
80539 Munchen
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)